Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
HCM
HCM
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HCM News
HUTCHMED to Announce 2025 Final Results on March 5
Feb 06 2026
Newsfilter
HUTCHMED and AstraZeneca's MET Inhibitor Approved, PFS Improved to 8.2 Months
Jan 14 2026
Globenewswire
HUTCHMED and AstraZeneca's Drug Approved, PFS Increased to 8.2 Months
Jan 14 2026
Newsfilter
ScinoPharm Secures FDA Approval for Glatiramer Acetate Injection in Multiple Sclerosis
Jan 09 2026
NASDAQ.COM
HUTCHMED Reports Phase 3 Data for Sovleplenib, Plans NDA Submission in 2026
Jan 07 2026
Benzinga
HUTCHMED's ESLIM-02 Trial Meets Primary Endpoint; NDA Submission Planned for 2026
Jan 07 2026
NASDAQ.COM
HUTCHMED Achieves Primary Endpoint in ESLIM-02 Trial for Sovleplenib
Jan 07 2026
NASDAQ.COM
HUTCHMED's Sovleplenib Achieves Primary Endpoint in wAIHA Phase III Trial in China
Jan 07 2026
Globenewswire
HUTCHMED Initiates Phase III Trial for Pancreatic Cancer Treatment
Jan 05 2026
NASDAQ.COM
HUTCHMED Initiates Phase III Trial for PDAC Treatment, First Patient Dosed
Jan 05 2026
Globenewswire
Harvest Care Medical Opens Two New Medical Cannabis Dispensaries in West Virginia
Jan 04 2026
Businesswire
HUTCHMED's Savolitinib NDA Accepted with Priority Review for Gastric Cancer
Dec 30 2025
NASDAQ.COM
HUTCHMED Submits NDA for Savolitinib in Gastric Cancer with Priority Review Granted
Dec 30 2025
Newsfilter
HUTCHMED's Savolitinib NDA for Gastric Cancer Receives Priority Review in China
Dec 30 2025
Globenewswire
HUTCHMED Secures Priority Review for Fanregratinib NDA in China
Dec 29 2025
NASDAQ.COM
Hutchmed Receives Priority Review for Fanregratinib NDA Targeting Advanced Cholangiocarcinoma
Dec 29 2025
NASDAQ.COM
Show More News
